Registration number: 13876617

Bio Scope Technologies Ltd

Contents

Balance Sheet	1
Notes to the Financial Statements	2 to 7

Bio Scope Technologies Ltd

(Registration number: 13876617)
Balance Sheet as at 31 December 2025

	Note	2025 £	2024 £
Fixed assets
Tangible assets	5	1,521,809	1,763,480
Current assets
Stocks		173,423	862,100
Debtors	6	366,761	277,046
Cash at bank and in hand		588,822	76,440
		1,129,006	1,215,586
Creditors: Amounts falling due within one year	7	(6,946,278)	(6,879,623)
Net current liabilities		(5,817,272)	(5,664,037)
Net liabilities		(4,295,463)	(3,900,557)
Capital and reserves
Called up share capital	9	220	150
Share premium reserve		2,389,881	989,951
Retained earnings		(6,685,564)	(4,890,658)
Shareholders' deficit		(4,295,463)	(3,900,557)

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 30 April 2026 and signed on its behalf by:
 

......................................... N J Razey Director

Bio Scope Technologies Ltd

Notes to the Financial Statements for the Year Ended 31 December 2025

1	General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Network House
Western Way
Bury St Edmunds
Suffolk
IP33 3SP

2	Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The financial statements are presented in sterling, which is the functional currency of the company.

Summary of disclosure exemptions

As permitted by the FRS 102 1A framework, the company has taken advantage of the disclosure exemptions available under that standard in relation to presentation of a cashflow statement,remuneration of key management personnel and presentation of changes in current tax and deferred tax assets/liabilities.

Going concern

Having reviewed the projected results and cash flow forecasts of the company the directors are confident that the company will be able to meet its cash obligations in the foreseeable future.

The company is in an intensive phase of research and development that brings a requirement for funds in addition to that needed for day to day trading. This funding has been provided in the year by the directors, shareholders and the parent company via both capital and loan funding. The company has the continued support of these stakeholders, who are committed to supporting the company as necessary through this phase.

The directors are therefore confident that the cash demands of the company will be satisfied, and it is therefore appropriate to prepare the financial statements on the going concern basis.

Bio Scope Technologies Ltd

Notes to the Financial Statements for the Year Ended 31 December 2025

Audit report

The Independent Auditor's Report was unqualified. The name of the Senior Statutory Auditor who signed the audit report on 12 May 2026 was Caroline Webster FCA, who signed for and on behalf of UHY Ross Brooke.

Revenue recognition

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Turnover represents the sales value of work completed at the balance sheet date excluding VAT. The Company's contractual obligations are performed over time therefore revenue is recognised as the contract activity progresses to reflect the Company's partial performance of its contractual obligations. Revenue is calculated by reference to the value of work performed.

Tax

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Leasehold property	10% straight line
Plant and machinery	25% reducing balance
Equipment	15% reducing balance

Bio Scope Technologies Ltd

Notes to the Financial Statements for the Year Ended 31 December 2025

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Stocks

There are different types of stock that the company hold which are valued as follows:

Recycling material
This is weighed at year-end and valued at cost per kilogram.

Work In Progress
Recycling material that is part way through the refining process is weighed at the year end, and a cost applied based on the original cost of the recycling material being processed. This cost does not include the cost of the processing or any overhead absorption.

Finished Goods
Any finished goods that consists of fully processed material is weighed at year-end and a conservative scrap material price is used based on the current London Metal Exchange prices.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers.

Leases

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3	Staff numbers

The average number of persons employed by the company (including directors) during the year, was 24 (2024 - 18).

Bio Scope Technologies Ltd

Notes to the Financial Statements for the Year Ended 31 December 2025

4	Exceptional items

The exceptional items disclosed relate to development costs, pre 2025 historic waste disposal and exceptional employment costs.

5	Tangible assets

	Leasehold property £	Plant and machinery £	Equipment £	Total £
Cost or valuation
At 1 January 2025	135,355	2,336,289	23,716	2,495,360
Additions	48,728	161,309	1,890	211,927
At 31 December 2025	184,083	2,497,598	25,606	2,707,287
Depreciation
At 1 January 2025	31,242	695,116	5,522	731,880
Charge for the year	18,224	432,377	2,997	453,598
At 31 December 2025	49,466	1,127,493	8,519	1,185,478
Carrying amount
At 31 December 2025	134,617	1,370,105	17,087	1,521,809
At 31 December 2024	104,113	1,641,173	18,194	1,763,480

Included within the net book value of land and buildings above is £134,617 (2024 - £104,113) in respect of long leasehold land and buildings.
 

6

Debtors

Current	2025 £	2024 £
Trade debtors	475	1,081
Prepayments and accrued income	299,085	108,959
Other debtors	67,201	167,006
	366,761	277,046

Bio Scope Technologies Ltd

Notes to the Financial Statements for the Year Ended 31 December 2025

7

Creditors

Creditors: amounts falling due within one year

	2025 £	2024 £
Due within one year
Trade creditors	131,717	148,885
Amounts owed to intercompany undertakings	6,495,664	6,368,965
Taxation and social security	18,926	34,083
Accruals and deferred income	294,991	327,690
Other creditors	4,980	-
	6,946,278	6,879,623